Skip to main content

Table 3 End organ abnormalities among patients with cytokine release syndrome

From: A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma

 

Total patients with CRS (N = 51)

All grades

Grades 1–2

Grades 3–4

Liver

 ALT high

25 (49)

24 (47)

1 (2)

 AST high

40 (78)

23 (45)

17 (33)

 Bilirubin high

22 (43)

22 (43)

0

Kidney

 Creatinine high

18 (35)

15 (29)

3 (6)

Pulmonary and vascular systems

 Hypotension

12 (24)

9 (18)

3 (6)

 Hypoxia

4 (8)

4 (8)

0

 Respiratory failure

1 (2)

0

1 (2)

Coagulopathya

 aPTT prolonged

31 (67)

28 (61)

3 (7)

 Fibrinogen decreased

17 (37)

0

17 (37)

  1. ALT alanine aminotransferase, aPTT activated partial thromboplastin time, AST aspartate aminotransferase, CRS cytokine release syndrome
  2. aOnly 46 patients had laboratory test results available (N = 46 was used as the denominator)